Literature DB >> 12836662

Recommendation for confidence interval and sample size calculation for the Pearl Index.

C Gerlinger1, J Endrikat, E A van der Meulen, T O M Dieben, B Düsterberg.   

Abstract

A new guideline on the clinical investigation of steroid contraceptives in women, which has been released by the European Agency for the Evaluation of Medicinal Products (EMEA), calls for the calculation of a confidence interval for the Pearl Index, a widely used measure to describe the effectiveness of a contraceptive method. However, the interpretation of the Pearl Index as a statistical parameter, for which a confidence interval can be calculated, needs further clarification. The guideline does not provide the necessary definitions. In this paper, two statistical models, the Bernoulli model and the Poisson model, are compared; both can be used for the calculation of the Pearl Index and its upper confidence limit. The Poisson model proved to be more suitable, because it can accommodate incomplete treatment cycles. Unambiguous definitions and statistical formulae for the calculation of overall Pearl Index and the Method Failure Pearl Index are given. Finally, the sample sizes required to fulfill the EMEA's guideline are given.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12836662

Source DB:  PubMed          Journal:  Eur J Contracept Reprod Health Care        ISSN: 1362-5187            Impact factor:   1.848


  9 in total

1.  Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.

Authors:  Sue Kelly; Emyr Davies; Simon Fearns; Carol McKinnon; Rick Carter; Christoph Gerlinger; Andrew Smithers
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20microg and drospirenone 3mg.

Authors:  D Cibula; U Karck; H G Weidenhammer; J Kunz; S Alincic; J Marr
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

3.  Safety data and beneficial effects of the combined oral contraceptive ethinylestradiol 0.03 mg/chlormadinone acetate 2 mg (Belara®): a 13-cycle, observational study in routine clinical practice.

Authors:  Daphnee S Pushparajah; Petra Röhm; Kornelia Höschen; Dagmar Albers; Christina Nowack
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

4.  Different Pearl Indices in studies of hormonal contraceptives in the United States: impact of study population.

Authors:  Christoph Gerlinger; James Trussell; Uwe Mellinger; Martin Merz; Joachim Marr; Ralf Bannemerschult; Ilka Schellschmidt; Jan Endrikat
Journal:  Contraception       Date:  2014-04-13       Impact factor: 3.375

5.  Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen.

Authors:  Diana Mansour; Carole Verhoeven; Werner Sommer; Edith Weisberg; Surasak Taneepanichskul; Gian Benedetto Melis; Inger Sundström-Poromaa; Tjeerd Korver
Journal:  Eur J Contracept Reprod Health Care       Date:  2011-10-13       Impact factor: 1.848

6.  Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: a multicenter, open-label, uncontrolled Phase III study.

Authors:  Qi Yu; Zirong Huang; Mulan Ren; Qing Chang; Zhongqi Zhang; Susanne Parke
Journal:  Int J Womens Health       Date:  2018-06-07

7.  Cross design analysis of randomized and observational data - application to continuation rates for a contraceptive intra uterine device containing Levonorgestrel in adolescents and adults.

Authors:  Tatsiana Vaitsiakhovich; Anna Filonenko; Richard Lynen; Jan Endrikat; Christoph Gerlinger
Journal:  BMC Womens Health       Date:  2018-11-09       Impact factor: 2.809

8.  Pattern recognition in menstrual bleeding diaries by statistical cluster analysis.

Authors:  Christoph Gerlinger; Jens Wessel; Gerd Kallischnigg; Jan Endrikat
Journal:  BMC Womens Health       Date:  2009-07-16       Impact factor: 2.809

9.  Estetrol-Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia.

Authors:  K Gemzell-Danielsson; D Apter; J Zatik; S Weyers; T Piltonen; L Suturina; I Apolikhina; M Jost; M D Creinin; J-M Foidart
Journal:  BJOG       Date:  2021-08-09       Impact factor: 7.331

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.